GENMAB A/S/S (GMXAY) Stock Price, News & Analysis

Company Overview

Genmab A/S/S is a global biotechnology company headquartered in Copenhagen, Denmark, specializing in the creation and development of antibody-based therapies. Since its founding in 1999, the company has built a strong research and development platform that spans next-generation antibody technologies. Genmab leverages proprietary platforms such as DuoBody® and HexaBody® to engineer bispecific and enhanced antibodies, aiming to address unmet medical needs in oncology and immunology.

The company’s flagship products include Darzalex® (daratumumab), approved for multiple myeloma in collaboration with Janssen Pharmaceuticals, and Kesimpta® (ofatumumab), developed with Novartis for relapsing forms of multiple sclerosis. Genmab’s pipeline extends to a range of investigational candidates, including bispecific T-cell engagers and antibody–drug conjugates, which are advancing through clinical trials for various hematologic and solid tumor indications. Its focus on high-value biologics underscores a strategy to deliver targeted therapies with the potential to improve patient outcomes.

Genmab operates across key markets in North America, Europe and Asia, supported by strategic partnerships with industry leaders. Collaborations with companies such as Janssen, Novartis and BioNTech provide Genmab with commercial reach and regulatory expertise, while enabling co-development of novel therapeutics. The company’s global footprint is reinforced by a network of research sites, manufacturing facilities and commercial affiliates that ensure broad patient access to its products.

Under the leadership of President and Chief Executive Officer Jan van de Winkel, PhD, Genmab maintains a strong scientific governance model, guided by an experienced board of directors chaired by Jan M. Petersen. The management team combines expertise in antibody engineering, clinical development and commercial strategy. With a commitment to innovation and collaboration, Genmab continues to advance its mission of bringing transformative antibody therapies to patients worldwide.

Key Stats

• Today's Range: $21.27 to $21.70
• 50-Day Range: $19.36 to $23.09
• 52-Week Range: $12.10 to $19.00
• Volume: 1.25 million shs
• Average Volume: 48,553 shs
• Market Capitalization: N/A
• P/E Ratio: 8.21
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GMXAY Stock Analysis - Frequently Asked Questions

How have GMXAY shares performed this year?

GENMAB A/S/S's stock was trading at $20.77 at the start of the year. Since then, GMXAY stock has increased by 3.0% and is now trading at $21.40.

How do I buy shares of GENMAB A/S/S?

Shares of GMXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GMXAY
• CIK: N/A
• Web: www.genmab.com
• Phone: 45 70 20 27 28
• Fax: N/A
• Employees: 1,660
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 8.21
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A